Fate Therapeutics, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
5.4
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
FATE
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (-52%).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $5.19 (+239.1%)
8 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
FATE
JNJ
—
Trailing P/E
26.3×
-1.5×
Forward P/E
17.9×
0.0%
Profit Margin
21.8%
0.0%
Gross Margin
68.0%
-51.8%
ROE
26.4%
-26.4%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
2.24
Beta
0.33
—
Price / Book
—
$178M
Market Cap
$546.9B
$1 – $2
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →